Laboratory of Anesthesia and Critical Care Medicine, Department of Anesthesiology, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Int J Nanomedicine. 2022 Jul 29;17:3371-3384. doi: 10.2147/IJN.S369706. eCollection 2022.
Ropivacaine as a conventional local anesthetic has been used more and more frequently in the treatment of postoperative pain, but its analgesic effect can only last for several hours. In order to fulfill the clinic requirement for long-term analgesia, a long-acting ropivacaine nanocrystal formulation was fabricated through the interaction between ropivacaine and a self-assembling peptide.
Transmission electron microscopy, dynamic light scattering, circular dichroism and fluorescence spectrometry were used to examine the structural changes caused by the interaction between ropivacaine and the peptide. Scanning electron microscopy, dynamic light scattering, Fourier transform infrared spectrometry, X-ray diffraction and optical microscopy were used to characterize the ropivacaine-peptide nanocrystal. In vitro drug release and pharmacokinetics study were conducted to evaluate the slow-release profile of the nanocrystal formulation. A rodent cutaneous trunci muscle reflex model was used to evaluate the nociceptive blockade effects, and histological analysis was used to evaluate the local toxicity. A rodent plantar incisional pain model was used to evaluate the analgesic effect.
Soluble ropivacaine monomers interacted with the Q11 peptide through π-π stacking and remolded its self-assembling structure, leading to the formation of drug/peptide nanoparticles which could be mineralized to form drug/peptide nanocrystals by adjusting the pH. Under physiological condition, the nanocrystals could release free ropivacaine slowly. As evaluated in rodent models, the anesthetic and analgesic effects of this formulation were significantly extended without causing toxicity.
Based on the interaction between ropivacaine and Q11, a controllable biomineralization process could be induced to obtain homogeneous nanocrystals, which could be used as an injectable long-acting analgesic formulation. This crystallization strategy utilizing the peptide-drug interaction also provided a promising pathway to fabricate long-acting formulations for many other small molecular drugs.
罗哌卡因作为一种常规局部麻醉剂,在术后疼痛治疗中的应用越来越频繁,但它的镇痛效果只能持续几个小时。为了满足临床对长效镇痛的需求,通过罗哌卡因与自组装肽的相互作用,制备了一种长效罗哌卡因纳米晶体制剂。
采用透射电子显微镜、动态光散射、圆二色性和荧光光谱法研究罗哌卡因与肽相互作用引起的结构变化。扫描电子显微镜、动态光散射、傅里叶变换红外光谱、X 射线衍射和光学显微镜用于表征罗哌卡因-肽纳米晶体。进行体外药物释放和药代动力学研究,以评估纳米晶体制剂的缓慢释放特性。使用啮齿动物皮肤横断肌反射模型评估伤害性阻断作用,组织学分析用于评估局部毒性。使用啮齿动物足底切口疼痛模型评估镇痛效果。
可溶的罗哌卡因单体与 Q11 肽通过π-π堆积相互作用,重塑其自组装结构,导致形成药物/肽纳米颗粒,通过调节 pH 值可以将其矿化为药物/肽纳米晶体。在生理条件下,纳米晶体可以缓慢释放游离罗哌卡因。在啮齿动物模型中评估表明,该制剂的麻醉和镇痛效果显著延长,且没有毒性。
基于罗哌卡因与 Q11 的相互作用,可以诱导可控的生物矿化过程来获得均匀的纳米晶体,可将其作为一种可注射的长效镇痛制剂。这种利用肽-药物相互作用的结晶策略也为许多其他小分子药物的长效制剂的制备提供了一个很有前途的途径。